Hematopoietic Stem Cell TransplantationBone Marrow TransplantationTransplantation, HomologousHematopoietic Stem CellsGraft vs Host DiseaseStem Cell TransplantationTransplantation, AutologousTransplantation ConditioningBone MarrowBone Marrow CellsStem CellsHematologic NeoplasmsTransplantation ChimeraWhole-Body IrradiationPeripheral Blood Stem Cell TransplantationTissue DonorsGraft SurvivalLeukemiaBusulfanHistocompatibility TestingLiver TransplantationHistocompatibilityHematopoiesisTreatment OutcomeAnemia, AplasticRecurrenceCord Blood Stem Cell TransplantationCombined Modality TherapyRetrospective StudiesHematopoietic Stem Cell MobilizationRemission InductionImmunosuppressive AgentsAntigens, CD34Graft vs Leukemia EffectCyclophosphamideTransplantation, IsogeneicKidney TransplantationLeukemia, Myeloid, AcuteHepatic Veno-Occlusive DiseaseMyeloablative AgonistsMice, Inbred C57BLBone and BonesTime FactorsChimerismCell DifferentiationHematologic DiseasesHLA AntigensTransplantation ImmunologyMyelodysplastic SyndromesLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor Cell Lymphoblastic Leukemia-LymphomaSevere Combined ImmunodeficiencySurvival AnalysisBone Marrow PurgingMesenchymal Stem Cell TransplantationMultiple MyelomaColony-Forming Units AssaySurvival RateGraft vs Tumor EffectGraft RejectionLymphocyte TransfusionCell TransplantationFlow CytometryDisease-Free SurvivalCell LineageLymphocyte DepletionMelphalanAcute DiseaseT-LymphocytesImmunosuppressionLymphoma, Non-HodgkinBone Marrow DiseasesGranulocyte Colony-Stimulating FactorLeukemia, MyeloidHeart TransplantationCytomegalovirus InfectionsRadiation ChimeraSiblingsAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesStem Cell NicheVidarabineAdult Stem CellsCells, CulturedUnrelated DonorsAntilymphocyte SerumLung TransplantationOrgan TransplantationSalvage TherapyCell SeparationFetal BloodCytarabineCyclosporineOpportunistic InfectionsEmbryonic Stem CellsPrognosisMesenchymal Stromal CellsTransplantationLeukocyte TransfusionImmunocompromised Host